Clinical Report: Tzield Approval Expands to Younger Patients

Overview

The FDA has approved teplizumab-mzwv (Tzield) for pediatric patients aged 1 year and older with stage 2 type 1 diabetes (T1D) to delay progression to stage 3. This decision is based on data from the PETITE-T1D Phase 4 study, which demonstrated safety and pharmacokinetics in younger children.

Background

Type 1 diabetes (T1D) is a progressive autoimmune condition leading to the destruction of insulin-producing beta cells. The ability to delay the onset of stage 3 T1D in younger patients is significant, as it can improve long-term health outcomes. The expanded indication for Tzield reflects ongoing efforts to provide effective therapies for pediatric populations at risk of developing T1D.

Data Highlights

Key Findings

• The FDA approved Tzield for children aged 1 year and older with stage 2 T1D.
• The approval was based on 1-year data from the PETITE-T1D Phase 4 study.
• Teplizumab is administered as daily IV infusions over 14 days.
• Stage 2 T1D is characterized by the presence of diabetes-related autoantibodies and dysglycemia.
• Teplizumab has previously received breakthrough therapy and orphan drug designations.

Clinical Implications

Healthcare providers should consider referring pediatric patients with stage 2 T1D for evaluation and potential treatment with Tzield. This approval may change management strategies for young patients at risk of progressing to stage 3 T1D.

Conclusion

The expanded indication for Tzield represents a significant advancement in the prevention of type 1 diabetes in younger populations, potentially altering the disease trajectory for many children.

Related Resources & Content

1. Sanofi, Press Release, 2026 -- Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
2. Teplizumab in Relatives at Risk for Type 1 Diabetes - PubMed
3. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 - PMC
4. The ASCO Post — Victory for Pediatric Regimens in Adolescents and Young Adults With ALL
5. Bone Marrow Transplantation — Influence of Age on the Efficacy of CAR-T Cell Treatments for Large B-Cell Lymphoma: Insights from the GLA/DRST Study
6. The ASCO Post — FDA Grants Accelerated Approval to Tazemetostat for Some Patients With Follicular Lymphoma
7. The ASCO Post — Novel Therapies and New Indications for Use in Treatment of Hematologic Malignancies
8. Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
9. Teplizumab in Relatives at Risk for Type 1 Diabetes - PubMed
10. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026 - PMC